Schroder Investment Management Group boosted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 0.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,456 shares of the medical instruments supplier’s stock after buying an additional 281 shares during the quarter. Schroder Investment Management Group’s holdings in Becton Dickinson and were worth $8,874,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Zions Bancorporation grew its position in Becton Dickinson and by 23.7% during the third quarter. Zions Bancorporation now owns 10,718 shares of the medical instruments supplier’s stock valued at $2,100,000 after buying an additional 2,050 shares during the period. SevenBridge Financial Group LLC lifted its holdings in Becton Dickinson and by 5.2% during the third quarter. SevenBridge Financial Group LLC now owns 12,579 shares of the medical instruments supplier’s stock valued at $2,465,000 after purchasing an additional 622 shares in the last quarter. Cigna Investments Inc. New lifted its holdings in Becton Dickinson and by 11.8% during the fourth quarter. Cigna Investments Inc. New now owns 9,741 shares of the medical instruments supplier’s stock valued at $2,085,000 after purchasing an additional 1,025 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in Becton Dickinson and by 17.5% during the third quarter. Macquarie Group Ltd. now owns 93,453 shares of the medical instruments supplier’s stock valued at $18,312,000 after purchasing an additional 13,900 shares in the last quarter. Finally, Westpac Banking Corp lifted its holdings in Becton Dickinson and by 23.9% during the fourth quarter. Westpac Banking Corp now owns 110,619 shares of the medical instruments supplier’s stock valued at $23,679,000 after purchasing an additional 21,369 shares in the last quarter. Institutional investors own 77.50% of the company’s stock.
In other news, VP John E. Gallagher sold 5,346 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $226.08, for a total value of $1,208,623.68. Following the transaction, the vice president now directly owns 9,391 shares of the company’s stock, valued at $2,123,117.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Timothy M. Ring sold 176 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $218.27, for a total transaction of $38,415.52. Following the completion of the transaction, the director now directly owns 170,688 shares in the company, valued at $37,256,069.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 279,231 shares of company stock worth $60,895,317. Insiders own 1.00% of the company’s stock.
Becton Dickinson and Co (NYSE:BDX) opened at $222.02 on Thursday. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93. The firm has a market cap of $59,110.00, a PE ratio of 89.16, a PEG ratio of 1.61 and a beta of 1.12. Becton Dickinson and Co has a 52 week low of $175.66 and a 52 week high of $248.39.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.41 by $0.07. The firm had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $2.33 earnings per share. research analysts anticipate that Becton Dickinson and Co will post 10.94 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.35%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is currently 120.48%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.